Differential effects of cholesterol levels on cognition according to body mass index in Parkinson’s disease

Table 3 Multivariate linear regression analyses for the association of total cholesterol levels with frontal/executive function according to body mass index

Variables	Under-/normal weight (BMI < 23)		Overweight (23 ≤ BMI < 25)		Obese (BMI > 25)
Variables	β (SE)	P	β (SE)	P	β (SE)	P
Intercept	− 1.088 (1.657)	0.513	5.591 (3.512)	0.115	0.407 (1.599)	0.800
Age	0.002 (0.011)	0.822	− 0.024 (0.011)	0.036	− 0.009 (0.011)	0.429
Female	0.104 (0.174)	0.550	0.266 (0.199)	0.184	− 0.008 (0.191)	0.967
Education	0.012 (0.019)	0.528	0.019 (0.019)	0.333	− 0.004 (0.021)	0.835
Symptom duration	0.001 (0.004)	0.802	− 0.003 (0.006)	0.649	− 0.001 (0.007)	0.930
Hypertension	0.047 (0.188)	0.802	− 0.061 (0.199)	0.761	0.356 (0.2)	0.080
Diabetes	− 0.37 (0.231)	0.112	− 0.159 (0.228)	0.488	− 0.19 (0.199)	0.343
Statin use	0.392 (0.195)	0.047	− 0.183 (0.208)	0.381	− 0.325 (0.186)	0.084
DAT-PP
WMHs burden	− 0.021 (0.01)	0.045	− 0.022 (0.013)	0.095	− 0.025 (0.014)	0.084
BMI	0.024 (0.058)	0.683	− 0.186 (0.143)	0.198	0.003 (0.052)	0.953
TC levels per 1 SD increase	0.205 (0.082)	0.013	0.078 (0.099)	0.436	− 0.213 (0.087)	0.017

Multivariate linear regression models were used to investigate the association between total cholesterol levels and cognition, while adjusting for age at symptom onset, sex, years of education, symptom duration, the presence of hypertension and diabetes, statin use, white matter hyperintensities, and BMI
β regression coefficient, BMI body mass index, DAT-PP dopamine transporter availability in the posterior putamen, SD standard deviation, SE standard error, TC total cholesterol, WMHs white matter hyperintensities

ISSN: 1758-9193